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Abstract
Purpose: The expression of desmogleins (DSGs), which are known to be crucial for establishing and maintaining the cell-cell
adhesion required for tissue integrity, has been well characterized in the epidermis and hair follicle; however, their
expression in other epithelial tissues such as prostate is poorly understood. Although downregulation of classical cadherins,
such as E-cadherin, has been described in prostate cancer tissue samples, the expression of desmogleins has only been
previously reported in prostate cancer cell lines. In this study we characterized desmoglein expression in normal prostate
tissues, and further investigated whether Desmoglein 2 (DSG2) expression specifically can serve as a potential clinical
prognostic factor for patients diagnosed with primary prostate cancer.
Experimental Design: We utilized immunofluorescence to examine DSG2 expression in normal prostate (n= 50) and in a
clinically well-characterized cohort of prostate cancer patients (n= 414). Correlation of DSG2 expression with clinico-
pathological characteristics and biochemical recurrence was analyzed to assess its clinical significance.
Results: These studies revealed that DSG2 and DSG4 were specifically expressed in prostatic luminal cells, whereas basal
cells lack their expression. In contrast, DSG1 and DSG3 were not expressed in normal prostate epithelium. Further analyses
of DSG2 expression in prostate cancer revealed that reduced levels of this biomarker were a significant independent marker
of poor clinical outcome.
Conclusion: Here we report for the first time that a low DSG2 expression phenotype is a useful prognostic biomarker of
tumor aggressiveness and may serve as an aid in identifying patients with clinically significant prostate cancer.
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Introduction
Desmosomes are a type of cell-cell anchoring junction found in
tissues that undergo a high degree of mechanical stress, and loss of
desmosomal adhesion is associated with diseases affecting the skin,
hair, and heart [1–13]. In the desmosome, the cadherin family of
proteins is represented by the so-called ‘‘non-classical’’ cadherins,
which include desmogleins (DSG 1–4) and desmocollins (DSC 1–
3) [14]. Desmogleins and desmocollins play a dual role in the
formation of desmosomes. In the extracellular space, desmogleins
and desmocollins on opposing cells interact in a heterophilic
calcium-dependent manner via their cadherin repeat domains.
Intracellularly, the cadherins bind to plakoglobin and plakophilin,
which in turn bind to desmoplakin. Desmoplakin then binds to
intermediate filaments, thereby securing the entire structure to the
cytoskeleton [15,16]. While clearly important in maintaining the
integrity of adult tissues, the role of desmosomal cadherins in
cancer progression is less well understood. Loss of heterozygosity
near the chromosomal region containing the desmosomal
cadherin gene cluster has been reported in esophageal cancer as
well as head and neck squamous cell carcinoma [17,18].
Alterations in the expression of desmogleins have been reported
for a variety of cancers. Reduced expression of DSG2 has been
reported in gastric and pancreatic carcinomas [19–21]. Converse-
ly, overexpression of DSG2 and DSG3 has been reported in
squamous cell carcinomas of the skin as well as head and neck
cancer, respectively [22,23].
The expression of desmosomal cadherins has been thoroughly
characterized in the epidermis, hair follicle, and arachnoidal tissue.
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While the expression of DSG2 is known to be ubiquitous in all
desmosome-forming tissues, the expression of the remaining
desmosomal cadherins outside of the epidermis and hair follicle
is poorly understood [24]. A study by Whittock and Bower in 2003
utilized RT-PCR to analyze the expression of DSG4 in a panel of
tissues and found that DSG4 could be detected in several tissues
including the prostate, suggesting that the desmoglein expression
profile of the prostate may extend beyond the ubiquitous
expression of DSG2 [25]. The downregulation or loss of cell-cell
adhesion proteins — such as the classical cadherin, E-cadherin —
is a common feature of a variety of cancers, including prostate
cancer, and can be caused by a variety of different mechanisms
[26,27]. Conversely, though the aberrant expression of desmogle-
ins has been reported in several types of cancer, the expression of
these cadherins in prostate cancer has only been reported in cell
lines to date [28–30]. In this study we characterize for the first time
the expression of desmogleins in normal human prostate tissue
specimens and determine the specific cell type in which prostate
specific desmogleins are expressed. We then analyze the expres-
sion of DSG2 in a well-characterized prostate cancer patient
cohort, and examine the association between DSG2 expression
and patients’ clinical outcome. Our results reveal that DSG2 and
DSG4 are specifically expressed in the luminal cells of normal
human prostate, whereas DSG1 and DSG3 are not expressed in
the prostate epithelium. Further, reduced expression of DSG2 was
found to be independently associated with a shorter biochemical
recurrence, highlighting the potential utility of DSG2 expression as
a prognostic biomarker of prostate cancer aggressiveness.
Materials and Methods
Ethics statement
Frozen normal human prostate tissue slides corresponding to
prostatic transitional zone with histologically confirmed areas of
normal glands from patients who underwent a radical prostatec-
tomy were obtained anonymously from the Columbia Tumor
Bank Service in accordance with the Institutional Review Board of
Columbia University Protocol #AAAB2447. The TMAs utilized
in this study were built in the Cordon-Cardo laboratory, and were
generated from 414 radical prostatectomy cases, originally
collected between September 2000 and January 2005 at the
Henry Ford Health System in Detroit, following an Institutional
Review Board’s approved protocol #1018 [31]. Each participant
completed a brief telephone interview (demographics and health
history), a food frequency questionnaire, and a face-to-face
interview on job related exposures. In addition, all participants
provided a blood sample for genetic analyses and for PSA testing.
Enrollment closed in spring of 2005, and the IRB remains open for
PSA follow-up (non-patient contact) for study subjects.
Cell Culture and RNA Isolation
The benign prostate epithelial BPH-1 cell line (a generous gift
from Dr. Ralph Buttyan, and commercially available through the
German Collection of Microorganisms and Cell Cultures; DSMZ,
Braunschweig, Germany) was cultured in RPMI with 10% fetal
bovine serum (FBS) (Invitrogen, Carlsbad, CA). Three human
metastatic prostate cancer cell lines were used in this study:
DU145, PC3 and LNCaP. The DU145 cell line (ATCC,
Manassas, VA) was cultured in MEM with 10% FBS (Invitrogen,
Carlsbad, CA). The PC3 cell line (ATCC, Manassas, VA) was
cultured in F12K with 10% FBS (Invitrogen, Carlsbad, CA). The
LNCaP cell line (ATCC, Manassas, VA) was cultured in RPMI
with 10% FBS (Invitrogen, Carlsbad, CA). To isolate RNA, cells
were washed in 1X PBS, trypsinized, and pelleted via centrifuga-
tion. Cells were grown four days past confluency prior to RNA
isolation as it has been previously reported that their full
desmoglein expression profile is reached at this time point [32].
The cell pellets were resuspended in 1X PBS and then pelleted via
centrifugation to wash. This wash step was repeated twice to
remove all traces of media prior to harvesting RNA. RNA was
then harvested using the RNeasy Mini Kit and QIAshredder
following the manufacturer’s protocol entitled ‘‘Purification of
Total RNA from Animal Cells Using Spin Technology’’ (Qiagen,
Valencia, CA).
Antibodies
Anti-DSG3 (clone 5H10) and DSG1 (clone 27B2) mouse
monoclonal antibodies have been previously described and were
given to us as a generous gift from Dr. James Wahl; both were
used at a dilution of 1:10 [33]. Anti-DSG2 mouse monoclonal
antibody (clone 10G11) was purchased from ARP, Inc (Belmont,
MA) and used at a dilution of 1:50 for immunofluorescence
analysis of normal prostate tissue and cell lines; anti-DSG1/2
mouse monoclonal antibody (clone DG3.10) was purchased from
Fitzgerald (Acton, MA) and used at a dilution of 1:20 for TMAs.
Anti-DSG4 guinea pig polyclonal antibody was generated by Dr.
Lutz Langbein and given to us as a generous gift, this antibody was
used at dilution of 1:2000. Anti-cytokeratin 14 (CK14) rabbit
polyclonal antibody was purchased from Covance (Princeton, NJ)
and used at a dilution of 1:1000. Anti-PSA mouse monoclonal
antibody was purchased from Dako (Carpinteria, CA) and used at
a dilution of 1:20. Anti-PSA rabbit monoclonal antibody was
purchased from Abcam (Cambridge, MA) and used at a dilution of
1:200. Anti-cytokeratins 8/18 (CK8/18) guinea pig polyclonal
antibody was purchased from Progen (Heidelberg, Germany) and
used at a dilution 1:100. Alexa Fluor 594 or Alexa Fluor 488
secondary antibodies were purchased from Invitrogen (Carlsbad,
CA) and were used at a dilution of 1:600.
RT-PCR
Total RNA from human normal skin and normal prostate (both
sourced from a single donor) was purchased commercially (Agilent
Technologies Inc., Santa Clara, CA). First strand cDNA was made
using Oligo dT and the SuperScript II First-Strand Synthesis
System (Invitrogen, Carlsbad, CA) following the manufacturer’s
instructions. PCR was performed using Platinum PCR Supermix
(Invitrogen, Carlsbad, CA) and primers for the transcripts of
interest (summarized in Table S1). The following PCR protocol
was used: step 1: 94uC for 3 min; step 2: 94uC for 30 sec, 56uC for
45 sec, 72uC for 2 min; step 3: 72uC for 10 min; repeat step 2 for
34 cycles. PCR products were electrophoresed on a 1% agarose/
1X TBE gel containing ethidium bromide and visualized using
Kodak Electrophoresis Documentation and Analysis System 120
Camera (Kodak, Rochester, NY).
qRT-PCR
RNA was harvested from cell lines of interest as described. First
strand cDNA was made using Oligo dT and the SuperScript III
First-Strand Synthesis System (Invitrogen, Carlsbad, CA) following
the manufacturer’s instructions. qRT-PCR was performed on a
Stratagene Mx3005P machine and analyzed using Stratagene
MxPro QPCR software (Stratagene, Santa Clara, CA). All
reactions were performed using QuantiTect SYBR Green PCR
Master Mix (Qiagen, Valencia, CA), 200 nM primers (summa-
rized in Table S1), and 10 ng cDNA in a 20 mL reaction volume.
The following PCR reaction was used: step 1: 95uC for 10 min;
step 2: 95uC for 15 sec, 60uC for 1 min; repeat step 2 for 40 cycles.
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All samples were run in quadruplicate, and samples were
normalized against an endogenous internal control, b-actin.
Immunofluorescence—Frozen Tissues and Cell Lines
Frozen normal human prostate tissue slides corresponding to
prostatic transitional zone with histologically confirmed areas of
normal glands from patients were used to characterize the
antibodies to detect desmoglein expression. Cell lines were grown
on glass coverslips (Fisher, Pittsburgh, PA) in 6-well tissue culture
plates (BD Falcon, Bedford, MA). Slides/coverslips were fixed in
cold 100% methanol for 15 min at 220uC followed by cold 100%
acetone fixation for 2 min at 220uC. Slides/coverslips were
washed in 1X phosphate buffered saline (PBS) with agitation,
permeabilized with 1% Triton-X100 in 1X PBS at room
temperature for 5 min, and washed again in 1X PBS with
agitation. Slides/coverslips were incubated in 0.1% Triton X-100/
1% bovine serum albumin (BSA)/1X PBS block at room
temperature for 1 hour, followed by primary antibody incubation
overnight at 4uC. The following day slides/coverslips were washed
in 1XPBS with agitation, then a 1:600 dilution of secondary
antibody, either Alexa Fluor 594 or Alexa Fluor 488 (Invitrogen,
Carlsbad, CA), was added and slides/coverslips were incubated at
room temperature for 45 min. Slides/coverslips were then washed
in 1XPBS with agitation, immersed briefly in water and mounted
using VECTASHIELD mounting medium with DAPI (Vector
Laboratories, Burlingame, CA).
Immunofluorescence Analysis of Tissue Microarray (TMA)
Sections
TMAs were built as follows: Hematoxylin & Eosin stained
sections from formalin-fixed paraffin-embedded (FFPE) prostatec-
tomy specimens were reviewed to identify viable, morphologically
representative areas of normal prostate glands and acinar
adenocarcinoma from which needle core samples could be taken.
From each specimen, triplicate adjacent tissue cores with
diameters of 0.6 mm were punched and arrayed onto a recipient
paraffin block using a precision instrument (Beecher Instruments,
MD). All punches were obtained from a focus with the highest
Gleason Score, and the majority of punches were taken from the
dominant tumor nodule — defined as the largest nodule with the
highest Gleason Score and stage in a specific prostatectomy
specimen. Follow-up data for all the cases regarding evidence of
biological recurrence was available for this study. Consecutive five-
micrometer sections of these TMA blocks were used for
immunofluorescence analysis, and the first section was stained
with Hematoxylin & Eosin to serve as a template for morphology.
The slides were deparaffinized and rehydrated, and antigen
retrieval was performed by heating slides in a steamer in citrate
buffer, pH 6.0 for 15 minutes. Slides were then washed once in 1X
PBS. Slides were incubated in 0.1% Triton X-100/1% BSA/1X
PBS blocking serum at room temperature for 1 hour followed by
primary antibody incubation overnight at 4uC. The following day,
slides were washed in 1XPBS with agitation, then a 1:600 dilution
of secondary antibody, either Alexa Fluor 594 or Alexa Fluor 488
(Invitrogen, Carlsbad, CA), was added and slides were incubated
at room temperature for 45 min. Slides were then washed three
times in 1X PBS+0.1% Triton X with agitation, washed three
times in 1X PBS, immersed briefly in water and mounted using
VECTASHIELD mounting medium with DAPI (Vector Labora-
tories, Burlingame, CA). CK8/18 expression was used to identify
all epithelial areas (both tumor and normal glands) in the cores and
the expression of the proteins of interest was scored by
determining the percentage of tumor cells with immunoreactivity
per tissue core (from 0% to 100%), without considering intensity of
signal. The evaluation was performed by a uropathologist (MCM)
following previously used methodology: tumor areas in the core
were identified first by DAPI, confirmed by the presence of CK8/
18 and then scored by establishing a percentage of tumors cells
with membrane expression of DSG2 [34].The average values of
the representative cores from each patient sample were then used
for statistical analyses. A positive cut-off of 60% was used to
perform statistical analyses of correlation with clinico-pathological
features and survival as this was the approximate median
expression value observed for DSG2 in this prostate cancer
cohort, as previously reported in the literature [35].
Prostate Cancer Cohort and Clinico-pathological
Characteristics
In this study we analyzed a cohort of 414 patients diagnosed
with primary prostate cancer. Clinico-pathological features of
these patients are summarized in Table 1. Mean age at diagnosis
was 61 years (range: 41–74.7 years). Most of the patients were
white (56%) or African-American (43%). Mean follow-up was 56.8
months (range: 1.4–123.6 months). Only 98 (24%) of the patients
showed a biochemical relapse, defined as having two consecutive
detectable rising PSA levels (.0.2 ng/ml) four weeks or more after
surgery. Biochemical recurrence free survival curves correspond-
ing to well known clinico-pathological risk factors such as Pre-
surgical PSA, Pathological Stage, Gleason Score, Angiolymphatic
Invasion and Perineural Invasion, are displayed in Figure S1.
Statistical Analysis
Statistical analysis was conducted using SPSS v18.0 (IBM,
Armonk, NY). The Student’s t-test was used to compare the
expression of the protein of interest in primary prostate cancer and
normal prostate tissue. Spearman’s rank correlation was used to
analyze the correlation between proteins of interest and clinico-
pathological features. Biochemical recurrence free survival was
analyzed using Kaplan-Meier survival curves, and curves were
compared using the log-rank test. Multivariate analysis including
DSG2 expression and clinico-pathological parameters was per-
formed using Cox proportional hazards model. A P-value #0.05
was considered statistically significant.
Results
Desmogleins are Specifically Expressed in Luminal Cells
of the Human Normal Prostate
As the expression of desmogleins in the prostate gland had not
been characterized to date, we began this study by examining the
full desmoglein expression profile in normal human prostate tissue,
using RT-PCR and immunofluorescence analyses. RT-PCR
analysis showed that most desmogleins could be readily detected
in normal human prostate at the RNA level, with the exception of
DSG1 which showed only faint mRNA expression (Figure 1A).
Immunofluorescence analysis revealed that only the expression of
DSG2 and DSG4 could be readily and consistently detected in the
prostate epithelium at the protein level (Figure 1B–C), whereas
DSG1 and DSG3 were not demonstrable in the normal prostate
epithelium (Figure S2).
Having established the expression of desmogleins in normal
human prostate, we aimed to determine the cell type specific
expression of DSG2 and DSG4. The glandular tissue of the
prostate is comprised of ducts and acini that are lined by a simple
cuboidal epithelium facing the lumen of the glands. In addition to
this secretory component, two other specialized cells are an
integral part of the prostate glandular structures, namely the basal
cells and the neuroendocrine cells [36,37]. Luminal cells secrete,
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among other molecules, prostate specific antigen (PSA) and
represent the main functional unit of the organ. These cells form
a continuous layer that lies on top of the basal cells. The basal cells
are characterized by the expression of high molecular weight
cytokeratins (CKs) — such as CK14 — and p63. Dispersed
throughout the acini is the third cell population, the neuroendo-
crine cells, the origin and function of which in the normal prostate
are not yet well defined.
Co-immunofluorescence analysis was performed to examine the
localization of DSG2 and DSG4 with CK14 specific basal cell
marker as well as the luminal specific protein, PSA. Co-
immunofluorescence analysis of DSG2 and CK14 shows that
DSG2 is robustly expressed in the luminal cells of the prostate and
that this expression rarely co-localizes with that of basal CK14
expression (Figure 2A–C). Analysis of DSG2 and PSA expression
revealed co-localization of both biomarkers in the luminal cells
(Figure 2D–F). The expression of DSG4 was very similar to that of
DSG2, showing strong expression in the luminal cells, rarely co-
localizing with basal CK14 expression (Figure 2G–I) but co-
localizing with luminal PSA expression (Figure 2J–L). Further-
more, the expression of DSG2 showed almost complete co-
localization with that of DSG4, with most luminal cells showing an
even level of expression for both desmogleins and some cells
showing a slightly higher expression level for one as compared to
the other (Figure 2M–O). Taken together these results illustrate
that the expression of DSG2 and DSG4 is mainly restricted to the
luminal cells of the human prostate epithelial glands.
DSG2 is Expressed in Human Prostate Cancer Cell Lines
Having characterized the expression of desmogleins in normal
human prostate tissue, we wished to focus on DSG2 for the
remainder of the study as this is the most widely expressed
desmoglein isoform — showing ubiquitous expression in all
desmosome forming tissues. Following our previous discovery that
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DSG2 is expressed in normal human prostate epithelium, we then
asked whether this protein is also expressed in human prostate
cancer cell lines. To examine this question, qRT-PCR was
performed on RNA extracted from three commercially available
and well characterized metastatic human prostate cancer cell lines
(Figure 3A). The cancer cell lines utilized for this portion of the
study include the LNCaP cell line, which was derived from a
prostate cancer that metastasized to the lymph node; the PC3 cell
line, which was derived from a prostate cancer that metastasized to
the bone; and the DU145 cell line, which was derived from a
prostate cancer that metastasized to the brain [38–40]. The BPH-
1 cell line served as a control for this study, since it is an
immortalized, non-tumorigenic prostatic epithelial cell line derived
from a patient with benign prostatic hyperplasia, a condition not
related to malignant prostate transformation [41]. The results of
this qRT-PCR analysis showed that DSG2 is expressed at different
levels in all cell lines examined. Interestingly, the expression of
DSG2 is greater in all the metastatic prostate cancer cell lines
examined than it is in the non-tumorigenic BPH-1 control.
Next, immunofluorescence analysis was utilized to examine the
expression of DSG2 in these metastatic human prostate cancer cell
lines at the protein level (Figure 3B–E). Cell border expression of
DSG2 was detected in BPH-1, LNCaP, and DU145 cells.
However, PC3 cells lacked the expression of DSG2 at the cell
border, while a small population of cells showed only a diffuse
granular staining for DSG2 in the cytoplasm (see insert
magnification in Figure 3D). These results are consistent with
and further refine the results of a previous study by Lang et al. in
which an antibody specific for both DSG1 and DSG2 was used to
examine desmoglein expression in LNCaP, PC3, and DU145 cells
[29,42]. The results of the qRT-PCR and immunofluorescence
analysis show that the expression of DSG2 is present in all prostate
cancer cell lines and that, in two of the three prostate cancer cell
lines examined, DSG2 localizes to the cell border suggesting that
desmosomal formation is retained in most metastatic prostate
cancer cell lines examined in vitro.
A Low DSG2 Phenotype is associated with Tumor
Progression in Patients with Primary Prostatic Carcinoma
As mentioned previously, while the loss of classical cadherin
expression has been described in prostate cancer, to date the
expression of desmosomal cadherins in prostate carcinoma tissue
samples has not been reported. To assess the percentage of cells
positive for DSG2 expression in prostate carcinoma as compared
to normal prostate tissue, immunofluorescence analysis of DSG2
expression was performed on prostate carcinoma TMAs (n=414)
as well as normal prostate TMAs (n=50). In addition to an
antibody for the protein of interest, an antibody for CK8/18 —
cytokeratins found in both normal prostate luminal epithelial cells
and adenocarcinoma cells — was also included on each TMA as a
means of identifying the epithelial cells in each sample.
A significant decrease in the percentage of cells positive for
DSG2 expression was found in prostate carcinomas as compared
to normal prostate (Table 2 and Figure S3). Normal prostate
epithelium was characterized by a high percentage of cells positive
for DSG2 expression (mean expression of 81.1%, median of
84.5%), whereas prostate tumor samples showed a significantly
lower percentage of DSG2 positive cells (mean expression of
57.5%, median of 66.7%; P=0.0002). A cut-off value of 60%
DSG2 positive cell expression was utilized, as this was the
approximate median expression value observed for DSG2 in the
prostate cancer cohort, and median has been previously and
widely used to perform survival analyses [35]. Using this cut-off
value, we observed that 96% of normal prostate tissue samples
were considered positive for DSG2, in comparison to only 46% of
the prostate carcinoma specimens studied. Notably, the amount of
cells that were positive for cell border expression of DSG2 was
generally higher in well differentiated areas of the tumor, while the
amount of cells showing this expression was often much lower in
poorly differentiated areas of the tumor (Figure 4A–L), a finding
that was further validated by Spearman’s rank correlation
(Table 3).
The correlation between the expression of DSG2 and the
clinico-pathological characteristics most commonly associated with
an aggressive prostate cancer phenotype, including serum Pre-
surgical PSA concentration, Gleason Score, and Pathological
Stage was then examined using Spearman’s rank correlation
(Table 3). Interestingly, there was a significant negative correlation
between DSG2 expression and Pre-surgical PSA concentration as
well as Gleason Score. These results revealed that a low-to-
negative DSG2 expression phenotype was associated with
increased serum Pre-surgical PSA concentration levels, as well as
with high Gleason Scores.
Decreased DSG2 Expression is an independent factor
associated with a Poor Clinical Outcome in Patients with
Primary Prostatic Carcinoma
Having examined the correlation between DSG2 phenotype
and clinico-pathological risk factors of prostate carcinoma, we next
determined whether DSG2 expression is associated with biochem-
ical recurrence free survival. Interestingly, patients whose tumors
expressed $ 60% DSG2 had a longer recurrence free survival
than those expressing ,60%, and the difference between these
two groups was statistically significant (Figure 4M, P=0.01). A
median time to biochemical recurrence of 103.7 months (CI 95%
interval: 87.72119.8 months) was observed for patients with ,
60% DSG2 expression phenotype, while those with $60% DSG2
expression phenotype did not reach the median time to
biochemical recurrence after a follow-up time of 123.6 months.
More importantly, when we performed a multivariate analysis, we
observed that DSG2 expression was an independent factor of
biochemical recurrence (HR=1.579, P=0.050), as well as the
classic clinico-pathological features: Gleason Score and Patholog-
ical Stage (Table 4). Taken together, these results show that
reduced DSG2 expression is an independent biomarker associated
with a shorter biochemical recurrence in prostate cancer, thereby
revealing the potential clinical utility of DSG2 as a prognostic
Figure 1. Desmoglein expression in normal human prostate. (A)
Clear expression of mRNA can be detected for most desmogleins, with
the exception of DSG1 which shows only faint expression. (B–C)
Representative immunofluorescence analyses of DSG2 (B) and DSG4 (C)
at the cell border of normal human prostatic glandular epithelium.
Original magnification: 200X. Scale bars correspond to 100 mm.
doi:10.1371/journal.pone.0098786.g001
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biomarker of tumor aggressiveness for patients affected with this
frequently occurring disease.
Discussion
The results presented in this study provide the first molecular
characterization of desmoglein expression in normal human
prostate, characterization of DSG2 in metastatic prostate cancer
Figure 2. DSG2 and DSG4 are specifically localized in the luminal cells of the normal prostate gland. (A–C) DSG2 is expressed in the
luminal cells of the prostatic glands and this expression rarely co-localizes with basal cell CK14 expression. (D–F) DSG2 co-localizes with PSA
expression in the luminal compartment of the gland. (G–I) DSG4 is also expressed in the luminal cells and rarely co-localizes with basal cell CK14
expression. (J–L) DSG4 expression co-localizes with luminal cell PSA expression. (M–O) The expression of DSG4 also shows almost complete co-
localization with that of DSG2 in the luminal cells. Original magnification: 200X. Scale bars correspond to 100 mm.
doi:10.1371/journal.pone.0098786.g002
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cell lines, and the first analysis of DSG2 expression in tissue
samples of primary prostatic carcinoma. The results here reported
reveal that while most desmogleins are distinctly expressed in the
human prostate at the RNA level, only DSG2 and DSG4 are
consistently identified at a high level in normal human prostate at
the protein level. Further, the expression of DSG2 and DSG4 was
found to be largely restricted to the luminal cells of the prostatic
glands. Prior examination of DSG4 has shown that DSG4 is
expressed in the most mechanically stressed layers of the epidermis
and hair shaft, thereby suggesting that this desmoglein may
provide stronger adhesion than the other desmoglein isoforms.
The presence of DSG4 in the prostatic glands may similarly
provide an additional level of adhesive strength in the desmosomes
of luminal cells beyond that provided by DSG2 alone. While an
examination of all desmogleins in prostate cancer was outside the
scope of this study, future examination of the remaining
desmoglein family members would likely yield a valuable
understanding of the role of desmosomal adhesion in prostate
cancer initiation and progression.
Interestingly, the expression of DSG2 is present in metastatic
prostate cancer cell lines in vitro. This observed expression of DSG2
is in line with a previous study conducted by Trojan et al. in which
microarray analysis revealed that DSG2 is overexpressed in the
highly metastatic LNCaP-C4-2 cell line as compared to the less
metastatic LNCaP cell line [28]. Taken together these results may
reflect the need for a re-expression of DSG2 in an aggressive
cancer in order to establish the cell-cell adhesion necessary to form
a metastatic tumor.
There is a lack of functional evidence regarding the role of
desmosomal cadherin based adhesion in cancer. However, in vitro
analysis of a non-adhesive, invasive fibroblast cell line showed that
the expression of desmosomal cadherins and plakoglobin was able
to generate adhesion and reduce the invasive capacity of the cell
line [15]. Treatment of these cells with peptides that blocked the
desmosomal cadherin adhesion site both blocked adhesion and
restored invasive capacity, suggesting that the observed adhesion
and reduced invasive capacity were desmosomal cadherin specific.
These results suggest a tumor suppressor role for desmosomal
cadherins and illustrate the possibility that desmosomal adhesion
may result in a similar impaired invasive capacity of cancer cells,
and that the loss of this adhesion may be required for the
progression of the disease. However, this tumor suppressor role is
controversial as in vivo analysis of transformed Dsg32/2 keratino-
Figure 3. DSG2 expression in human metastatic prostate cancer cell lines. (A) DSG2 expression is detected in all cell lines examined,
including the normal immortalized prostate cell line BPH-1. Data is represented as mean6 SD. **P,0.01; *** P,0.001. (B–E) DSG2 is expressed at the
cell border of LNCaP and DU145 cells; however, cell border expression is not detected in PC3 cells with only some cells showing faint, punctate, and
diffuse staining (insert magnification; shown at 2.5X). Original magnification: 200X. Scale bars correspond to 100 mm.
doi:10.1371/journal.pone.0098786.g003
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Figure 4. Low expression of DSG2 is a poor prognosis biomarker for patients with prostatic carcinoma. (A–L) Representative
immunofluorescence analysis of DSG2 and CK8/18 in prostate cancer. (D, E–H) TMAs showing high DSG2 expression in the cell border of well
differentiated areas of the tumor (panel D, inside yellow dashed line). (D, I–L) TMAs showing low DSG2 expression in poorly differentiated areas of
the tumor (panel D, shown in the remainder of the tumor outside of the yellow dashed line). Original magnification: 200X. Scale bars correspond to
100 mm. (M) Patients expressing higher levels of DSG2 had a significantly longer recurrence free survival than those expressing lower levels of DSG2
(P=0.01).
doi:10.1371/journal.pone.0098786.g004
Table 2. Expression of DSG2 in prostate cancer as compared to normal prostate.
DSG2 expression Cancer Normal P-value*
Mean 57.5 81.1 0.0002
Standard Deviation 25.7 9.9
Median 66.7 84.5
Interquartile Range 40–76.7 80.0–86.7
*P-value determined using Student’s T-test.
doi:10.1371/journal.pone.0098786.t002
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cytes showed impaired tumor growth, thereby suggesting an
alternative tumor promoting role for desmosomal cadherins [43].
Prior to this study, the expression of desmogleins in prostate
cancer tissue samples had not been reported. Given that
desmosomes are involved in cell-cell adhesion in prostatic
epithelium, an understanding of the expression of desmogleins
would provide a deeper insight into the role of anchoring junctions
in prostate cancer progression. Interestingly, DSG2 expression was
significantly reduced in prostate cancer as opposed to normal
prostate. Specifically, the expression of DSG2 was generally high
in well differentiated areas of the tumor (low Gleason Score) and
low in poorly differentiated areas of the tumor (high Gleason
Score). Consistent with this observation, the results of the
Spearman’s rank correlation show that there is a negative
correlation between DSG2 phenotype and serum Pre-surgical
PSA concentration, Gleason Score, and Pathological Stage. Taken
together these results suggest that DSG2 expression is reduced in
primary prostate tumors with an aggressive biological behavior.
Furthermore, the results of the Kaplan-Meier biochemical
recurrence free survival curves denote that patients with a reduced
DSG2 expression phenotype have a worse prognosis and poorer
clinical outcome than patients whose prostate carcinoma is
characterized by a high DSG2 expression phenotype; a finding
further confirmed by multivariate analysis. In sum, these results
highlight a potentially critical role for DSG2 based cell-cell
adhesion in the progression of prostate carcinoma, and demon-
strate that DSG2 may be a useful predictive biomarker of clinically
significant prostate cancer.
Supporting Information
Figure S1 Biochemical recurrence free survival curves
for the classical prostate cancer recurrence risk factors
in the studied cohort of 414 patients. (A) Pre-surgical PSA,
(B) Pathological Stage, (C) Gleason Score, (D) Angiolymphatic
Invasion, and (E) Perineural Invasion.
(TIF)
Figure S2 DSG1 and DSG3 are not expressed in normal
prostate. (A–C) Representative DSG1 expression in a normal
prostate gland. (D–F) Representative DSG3 in a normal prostate
gland. DAPI is depicted in left panels, DSGs in center panels,
merged images in right panels. Original magnification: 200X.
Scale bars correspond to 100 mm.
(TIF)
Figure S3 DSG2 differential expression in normal
prostate and prostate cancer. Box plot illustrates that
DSG2 is significantly expressed at higher levels in normal prostate
as compared to prostate cancer.
(TIF)
Table 3. Correlation between DSG2 and clinico-pathological characteristics.
PSA Gleason Score TNM Stage DSG2
PSA Correlation 1.000 0.294** 0.256** 20.161**
Sig. (2-tailed) . ,0.0001 ,0.0001 0.004
N 410 400 410 316
Gleason Score Correlation 1.000 0.363** 20.122*
Sig. (2-tailed) . ,0.0001 0.031
N 402 402 313
TNM Stage Correlation 1.000 20.084





*Spearman’s rho correlation is significant at P,0.05 level and **P,0.01 level (2-tailed).
doi:10.1371/journal.pone.0098786.t003
Table 4. Multivariate analyses in the 414 patient cohort.
HR* 95% CI** P-value***
DSG2 1.579 0.99622.503 0.050
Pre-surgical PSA 1.340 0.95621.878 0.089
Gleason Score 2.036 1.51822.732 ,0.0001
Pathological Stage 2.296 1.49923.517 ,0.0001
Angiolymphatic invasion 0.623 0.24821.570 0.316
Perineural invasion 0.973 0.51521.838 0.933
*HR: Hazard Ratio;
**CI: Confidence Interval;
***P-value determined by Cox proportional hazards model.
doi:10.1371/journal.pone.0098786.t004
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Table S1 RT-PCR Primers and qRT-PCR Primers.
(DOC)
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